Merck Announces First-Quarter 2012 Financial Results
2012 First-Quarter Non-GAAP EPS Increased Eight Percent Over Prior Year to $0.99, Excluding Certain Items; GAAP EPS of $0.56 Worldwide Sales Grew One Percent to $11.7 Billion Driven by Growth of Three Percent in Pharmaceuticals (Six Percent, Excluding the Impact of the J&J Arbitration Settlement), Eight Percent in Animal Health and Seven Percent in Consumer Care Strong Growth Across All Major Businesses Partially Offset by Reductions in Alliance Revenue and Third-Party Manufacturing Sales Double-Digit Global Growth for JANUVIA, JANUMET, GARDASIL, ISENTRESS and Strong Performance for VICTRELIS Reaffirmed 2012 Full-Year Non-GAAP EPS Target of $3.75 to $3.85, Excluding Certain Items; GAAP EPS Range of $2.04 to $2.30 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2012. $ in millions, except EPS amounts First Quarter 2012 First Quarter 2011 Sales $11,731 $11,580 GAAP EPS 0.56 0.34 Non-GAAP EPS
https://www.merck.com/news/merck-announces-first-quarter-2012-financial-results/
Merck Announces Full-Year and Fourth-Quarter 2011 Financial Results
- 2011 Full-Year Non-GAAP EPS of $3.77, Excluding Certain Items; GAAP EPS of $2.02; Fourth-Quarter Non-GAAP EPS of $0.97, Excluding Certain Items; GAAP EPS of $0.49 - 2011 Full-Year Worldwide Sales Grew Four Percent to $48.0 Billion, Including Two Percent from Foreign Exchange; Fourth-Quarter Worldwide Sales Grew Two Percent to $12.3 Billion - Full-Year and Fourth-Quarter Double-Digit Global Growth for JANUVIA, JANUMET, ISENTRESS and GARDASIL - Company plans to file five major products for approval between 2012 and 2013 - 2012 Full-Year Non-GAAP EPS Target of $3.75 to $3.85, Excluding Certain Items; GAAP EPS Range of $2.04 to $2.30 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2011. $ in millions, except EPS amounts Fourth <br />Quarter <br />2011 Fourth Quarter 2010 Year Ended <br />Dec. 31, <br />2011 Year Ended Dec. 31, 2010 Sales $12,294 $12,094 $48,047 $45,987 GAAP EPS 0.49
https://www.merck.com/news/merck-announces-full-year-and-fourth-quarter-2011-financial-results/
Merck Announces Third Quarter 2011 Financial Results
Double-Digit Non-GAAP EPS Growth in Third Quarter 2011; Non-GAAP EPS of $0.94; GAAP EPS of $0.55 Worldwide Sales Growth of 8 Percent, Including 5 Percent From Foreign Exchange; Increase Driven by Pharmaceutical and Animal Health Sales Double-Digit Global Growth for JANUVIA, GARDASIL, SINGULAIR, JANUMET and ISENTRESS JUVISYNC and VICTRELIS and Other Product Launches Underway Company Raises Lower End of 2011 Non-GAAP EPS Range; Provides New Range of $3.72 to $3.76; Also Updates GAAP EPS Range to $2.03 to $2.20; Expects Full Year 2011 Revenue Growth in the Mid-Single Digit Range Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2011. $ in millions, except EPS amounts Third Quarter 2011 Third <br />Quarter <br />2010 Sales $ 12,022 $ 11,125 GAAP EPS 0.55 0.11 Non-GAAP EPS that excludes items listed below 1 0.94 0.85 GAAP Net Income 2 1,692 342 Non-GAAP Net Income that excludes items
https://www.merck.com/news/merck-announces-third-quarter-2011-financial-results/
Merck Announces Second Quarter 2011 Financial Results
Double-Digit Non-GAAP EPS Growth in Second Quarter 2011: Non-GAAP EPS of $0.95; GAAP EPS of $0.65 Total Company and Pharmaceutical Sales Grow by 7 Percent, Including Foreign Exchange Double-Digit Global Growth Continues for JANUVIA, JANUMET, REMICADE, and ISENTRESS VICTRELIS and Other Product Launches Underway Company Raises Lower End of its 2011 Non-GAAP EPS Range; Provides New Range of $3.68 to $3.76; Also Updates GAAP EPS Range to $1.95 to $2.17 Company Announces New Phase of Merger Restructuring Program Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2011. $ in millions, except EPS amounts Second Quarter 2011 Second Quarter 2010 Sales $ 12,151 $ 11,346 GAAP EPS 0.65 0.24 Non-GAAP EPS that excludes items listed below 1 0.95 0.86 GAAP Net Income 2 2,024 752 Non-GAAP Net Income that excludes items listed below 1, 2 2,950 2,708 Non-GAAP (generally accepted accounting
https://www.merck.com/news/merck-announces-second-quarter-2011-financial-results/
Merck Announces First Quarter 2011 Financial Results
Double-Digit EPS Growth in First Quarter 2011: Non-GAAP EPS of $0.92; GAAP EPS of $0.34 Double-Digit Global Growth for JANUVIA, JANUMET, SINGULAIR, REMICADE, NASONEX and ISENTRESS; Key Product Launches Underway Pharmaceutical, Animal Health and Consumer Care Divisions All Contributed Solid Revenue Growth Company Updates Full-Year 2011 EPS Targets: Non-GAAP EPS Range of $3.66 to $3.76; GAAP EPS Range of $2.04 to $2.39 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011. $ in millions, except EPS amounts First <br />Quarter <br />2011 First Quarter 2010 Sales $ 11,580 $ 11,422 GAAP EPS 0.34 0.09 Non-GAAP EPS that excludes items listed below 1 0.92 0.83 GAAP Net Income 2 1,043 299 Non-GAAP Net Income that excludes items listed below 1, 2 2,861 2,608 Non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.92 excludes purchase accounting
https://www.merck.com/news/merck-announces-first-quarter-2011-financial-results/
Merck Announces Fourth Quarter and Full Year 2010 Financial Results
Company Reports Double-Digit Non-GAAP EPS Growth in the Fourth Quarter Fourth Quarter Non-GAAP EPS of $0.88, Excluding Certain Items; GAAP EPS of $(0.17); Full Year 2010 Non-GAAP EPS of $3.42, Excluding Certain Items; GAAP EPS of $0.28 Continued Strong Global Growth from JANUVIA/JANUMET, SINGULAIR, ISENTRESS, REMICADE Realized More than $2 Billion in Net Synergy Savings in 2010; On Track to Reach $3.5 Billion in Annual Savings by End of 2012 Company Withdraws Previous Long-Term Non-GAAP EPS Target; Full Year 2011 Non-GAAP EPS Target of $3.64 to $3.76, Excluding Certain Items; GAAP EPS Range of $2.05 to $2.33 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses. The
https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2010-financial-results/
Merck Announces Third-Quarter 2010 Financial Results
Non-GAAP EPS of $0.85, Excluding Certain Items; GAAP EPS of $0.11, for the Quarter Strong Sales of Key Pharmaceutical Products; Solid Performance by Consumer Care and Animal Health Units New Product Launches and Progressing Pipeline Drive Business Momentum On Track to Meet Synergy Target of $3.5 Billion in Annual Savings by End of 2012 Raised Lower End of 2010 Non-GAAP EPS Target Range Due to Solid Year-to-Date Performance; Long-Term Non-GAAP EPS Growth Rate Target Reaffirmed Merck & Co., Inc. (NYSE: MRK) today announced financial results for the third quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the third quarter of $0.85, which excludes purchase accounting adjustments, restructuring costs, merger-related expenses and a $950 million legal reserve. Third-quarter GAAP EPS was $0.11. Worldwide sales for the third quarter of 2010 were $11.1 billion. Net income1 for the third quarter was $342 million. For the first
https://www.merck.com/news/merck-announces-third-quarter-2010-financial-results/